Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that high-dose spironolactone frequently caused metrorrhagia in women with idiopathic hirsutism, leading the authors to suggest lower starting doses or additional hormonal therapy.

β-estradiol slows hair growth in mice.

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

In this study, low-dose finasteride (2.5 mg/day) significantly reduced hirsutism scores in women over 12 months without significant hormonal changes or serious side effects.

This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.

The researchers reported that metabolism of progesterone to 3α,5α-THP in the hippocampus is important for its antiseizure effects in ovariectomized rats.

This study found that oral contraceptive pills improve mild hirsutism, while flutamide and spironolactone are beneficial for more severe cases, but other therapies show inconsistent or no benefit.

In this study, Korean women with female pattern hair loss who used a combination of topical 0.025% 17α-estradiol and 3% minoxidil saw significant increases in total hair count and hair caliber over six months.

In this study, estetrol (E4) treatment was associated with increased hair growth in ex vivo human hair follicles, suggesting its potential as a treatment for hair loss disorders.

This study found that spironolactone significantly reduced hirsutism scores in women with idiopathic hirsutism compared to finasteride and cyproterone acetate but showed no significant difference among women with PCOS compared to flutamide and finasteride, and it was well tolerated overall.

This brief report discusses spironolactone used as a treatment for hirsutism in a hyperandrogenic woman, offering no new clinical findings and focusing on its antiandrogenic properties.

This study found that spironolactone significantly reduced hair growth in hirsute women, with noticeable effects in 3-5 months, and decreased serum testosterone levels in all participants.

In this retrospective study, spironolactone improved acne in 86% of patients while showing minimal side effects, suggesting it as a safe treatment option for postadolescent acne with a low risk of short-term adverse effects like hyperkalemia.

This analysis reports no significant differences between spironolactone and metformin for managing PCOS, noting spironolactone remains a potential off-label option for patients unable to use hormonal contraceptives, but larger studies are necessary to confirm its efficacy.

This study suggests that Aldactone may be more effective than Diane in reducing hair growth, despite having minimal impact on hormone levels.

This study found that in non-obese women with moderate body hair growth, DHEA-S and prolactin levels were higher, and SBP was lower compared to controls, which may inform treatment decisions.

This article notes the lack of physician-reported outcome studies supporting the efficacy of off-label spironolactone in treating female pattern hair loss, despite its common prescription alongside FDA-approved topical minoxidil.

This article discusses the positive effects of estrogens and progestagens on various general diseases, but reports no new clinical results; the mechanisms and treatment approaches are presented.

In this study, a treatment regimen combining cyproterone acetate and ethinyl estradiol significantly improved acne and seborrhoea in most women after three months, but had varied effects on hirsutism and alopecia.

This review evaluates previous studies on androgen-progestin combinations for male contraception, concluding that long-acting injectable formulations appear promising due to their effectiveness and minimal short-term adverse effects.

This study found that treatment with oral contraceptives containing 35mg ethinylestradiol and 2mg cyproterone acetate significantly reduced serum AMH levels in women with clomiphene citrate-resistant polycystic ovary syndrome, unlike metformin.

This study found that spironolactone, flutamide, and finasteride are similarly effective in reducing hair diameter and Ferriman-Gallwey scores in women with hirsutism over a 6-month treatment period.

This study found that flutamide was more effective than spironolactone in reducing symptoms of hirsutism and related conditions in premenopausal women, with fewer discontinuations due to side effects.

This review found that hormonal therapies, including FDA-approved combined oral contraceptive pills and spironolactone, are effective and well-tolerated treatments for acne vulgaris in adolescents with or without endocrine disorders, providing alternative options to antibiotics.

This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.

Equol may help with antiaging and skin health by boosting collagen and blocking certain hormones.

This study observed that 62% of premenopausal women with female pattern hair loss reported improvement when treated with oral finasteride and an oral contraceptive containing drospirenone and ethinyl estradiol.

Allopregnanolone, a progesterone metabolite, helps reduce restraint effects on behavior.

This research reports that oral contraceptives may cause melasma in 24-29% of users, with minimal improvement after stopping the drug and limited effectiveness of hydroquinone treatment.